Danaher Corporation Second Quarter 2025 Earnings Release July 22, 2025 -- 1 of 28 -- 2 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward- looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the healthcare industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the healthcare industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory changes or uncertainty and military conflicts), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2024 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the second quarter of 2025. These forward-looking statements speak only as of the date of this presentation (July 22, 2025) and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise. With respect to the non-GAAP financial measures referenced in the following presentation, calculations of these measures, explanations of what these measures represent, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, as applicable, and other information relating to these non-GAAP measures required by SEC Regulation G can be found in the accompanying information at the end of this presentation or in the “Investors” section of Danaher’s web site, www.danaher.com, under the subheading “Quarterly Earnings.” In addition, in addressing various financial metrics the presentation describes certain of the more significant factors that impacted year- over-year performance. For additional factors that impacted year-over-year performance, please refer to our earnings release and the other related presentation materials supplementing today’s call, as well as our second quarter Form 10-Q, all of which are available in the “Investors” section of Danaher’s web site under the subheadings “Financial Reports” and “Quarterly Earnings." All references in this presentation (1) to financial metrics relate only to the continuing operations of Danaher’s business, unless otherwise noted; and (2) to “growth” or other period-to-period changes, refer to year- over-year comparisons unless otherwise indicated. We may also describe certain products and devices which have applications submitted and pending for certain regulatory approvals. -- 2 of 28 -- 3 Second Quarter 2025 Performance Summary $5,743 $5,936 Q2 2024 Q2 2025 Throughout this presentation, with respect to revenue performance, for the definitions of "Acquisitions", "Divestitures", “Core” and “FX”, please refer to Danaher’s most recent Quarterly and Annual Reports filed with the SEC, which are available in the “Investors” section of Danaher’s website under the subheading "Financial Reports”. Revenue +3.5% Core +1.5% FX +2.0% $1.72 $1.80 Q2 2024 Q2 2025 Adjusted Diluted Net Earnings Per Common Share +4.7% ($ millions) 27.3% 27.3% Q2 2024 Q2 2025 Adjusted Operating Profit Margin Flat -- 3 of 28 -- 4 Second Quarter 2025: Biotechnology $1,713 $1,850 Q2 2024 Q2 2025 Revenue 39.5% 41.0% Q2 2024 Q2 2025 Adjusted Operating Profit Margin +150 BPS 8.0% Core +6.0% FX +2.0% ($ millions) -- 4 of 28 -- 5 Second Quarter 2025: Life Sciences $1,770 $1,777 Q2 2024 Q2 2025 Revenue 21.1% 19.3% Q2 2024 Q2 2025 Adjusted Operating Profit Margin +0.5% ($ millions) Core -2.5% Acquisitions +1.5% FX +1.5% -180 BPS -- 5 of 28 -- 6 Second Quarter 2025: Diagnostics $2,260 $2,309 Q2 2024 Q2 2025 Revenue 26.7% 26.1% Q2 2024 Q2 2025 Adjusted Operating Profit Margin -60 BPS +2.0% ($ millions) Core +2.0% Divestitures -0.5% FX +0.5% -- 6 of 28 -- 7 Guidance -- 7 of 28 -- 8 Q&A -- 8 of 28 -- -- 9 of 28 -- DANAHER CORPORATION RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES AND SUPPLEMENTAL FORWARD-LOOKING INFORMATION THREE AND SIX-MONTH PERIODS ENDED JUNE 27, 2025 AND JUNE 28, 2024 -- 10 of 28 -- TABLE OF CONTENTS Page 1 Sales Growth (Decline) by Segment and Core Sales Growth (Decline) by Segment 2 Forecasted Core Sales Growth, Adjusted Operating Profit Margin and Adjusted Diluted Net Earnings Per Common Share 3 Segment Sales, Operating Profit and Adjusted Operating Profit 4 Non-GAAP Profitability Measures 8 Other Non-GAAP Adjusted P&L Measures 13 Operating Profit Margins and Year-Over-Year Core Operating Profit Margin Changes 14 Total Cash Flow, Free Cash Flow, Operating Cash Flow to Net Earnings Conversion Ratio and Free Cash Flow to Net Earnings Conversion Ratio 15 Statement Regarding Non-GAAP Measures FORWARD-LOOKING STATEMENTS DISCLOSURE Statements in this document that are not strictly historical, including any statements regarding anticipated performance for any fiscal period that has not been completed, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the healthcare industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the healthcare industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory changes or uncertainty and military conflicts), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2024 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the second quarter of 2025. These forward-looking statements speak only as of the date of this document (July 22, 2025) and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise. -- 11 of 28 -- % Change Three-Month Period Ended June 27, 2025 vs. Comparable 2024 Period Segments Total Company Biotechnology Life Sciences Diagnostics Total sales growth (GAAP) 3.5 % 8.0 % 0.5 % 2.0 % Impact of: Acquisitions/divestitures — % — % (1.5) % 0.5 % Currency exchange rates (2.0) % (2.0) % (1.5) % (0.5) % Core sales growth (decline) (non-GAAP) 1.5 % 6.0 % (2.5) % 2.0 % % Change Six-Month Period Ended June 27, 2025 vs. Comparable 2024 Period Segments Total Company Biotechnology Life Sciences Diagnostics Total sales growth (decline) (GAAP) 1.0 % 7.0 % (1.5) % (0.5) % Impact of: Acquisitions/divestitures — % — % (1.5) % 0.5 % Currency exchange rates — % (0.5) % (0.5) % — % Core sales growth (decline) (non-GAAP) 1.0 % 6.5 % (3.5) % — % DANAHER CORPORATION Sales Growth (Decline) by Segment and Core Sales Growth (Decline) by Segment 1 -- 12 of 28 -- With respect to forecasted core sales growth, adjusted operating profit margin and adjusted diluted net earnings per common share, the Company does not reconcile these non-GAAP measures to their respective, comparable GAAP measure because (except for estimated amortization of acquisition-related intangible assets of $1.7 billion for the year ending December 31, 2025 and estimated currency translation contributions to revenue growth of 1.5% (for the third quarter 2025) and 1.0% (for the full year 2025), assuming the currency exchange rates in effect as of June 27, 2025) the additional elements that would be reflected in any such GAAP measures (such as the impact of currency exchange rates on profitability, acquisitions, divested product lines, discrete tax adjustments, impairments and gains and losses on investments) are difficult to predict and estimate and are often dependent on future events that may be uncertain or outside of our control. The impact of these additional elements could be material to our results computed in accordance with GAAP. % Change Three-Month Period Ending September 26, 2025 vs. Comparable 2024 Period % Change Year Ending December 31, 2025 vs. Comparable 2024 Period Core sales growth (non-GAAP) +Low-single digit 3.0 % Three-Month Period Ending September 26, 2025 Adjusted operating profit margin (non-GAAP) ~25.5 % Year Ending December 31, 2025 Adjusted diluted net earnings per common share (non-GAAP) $7.70 - $7.80 DANAHER CORPORATION Forecasted Core Sales Growth, Adjusted Operating Profit Margin and Adjusted Diluted Net Earnings Per Common Share 2 -- 13 of 28 -- Sales (GAAP) Biotechnology $ 1,850 $ 1,713 $ 3,462 $ 3,237 Life Sciences 1,777 1,770 3,457 3,515 Diagnostics 2,309 2,260 4,758 4,787 Total Company $ 5,936 $ 5,743 $ 11,677 $ 11,539 Operating Profit (Loss) (GAAP) Biotechnology $ 531 $ 462 $ 972 $ 787 Life Sciences (239) 233 (38) 468 Diagnostics 554 556 1,272 1,386 Other (86) (83) (172) (161) Total Company $ 760 $ 1,168 $ 2,034 $ 2,480 Amortization of Intangible Assets (GAAP) Biotechnology $ 228 $ 214 $ 441 $ 432 Life Sciences 150 140 299 281 Diagnostics 48 48 96 96 Total Company $ 426 $ 402 $ 836 $ 809 Other Operating Profit Adjustments1 Biotechnology $ — $ — $ 15 $ — Life Sciences 432 — 432 25 Diagnostics — — — — Other — — — — Total Company $ 432 $ — $ 447 $ 25 Adjusted Operating Profit (Non-GAAP)2 Biotechnology $ 759 $ 676 $ 1,428 $ 1,219 Life Sciences 343 373 693 774 Diagnostics 602 604 1,368 1,482 Other (86) (83) (172) (161) Total Company $ 1,618 $ 1,570 $ 3,317 $ 3,314 Three-Month Period Ended Six-Month Period Ended June 27, 2025 June 28, 2024 June 27, 2025 June 28, 2024 1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments. 2 Adjusted Operating Profit (Non-GAAP) is defined as Operating Profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined). DANAHER CORPORATION Segment Sales, Operating Profit and Adjusted Operating Profit ($ in millions) 3 -- 14 of 28 -- Three-Month Period Ended June 27, 2025 Biotechnology Life Sciences Diagnostics Other Total Company Net Earnings (GAAP) $ 555 Interest, Net 63 Other Nonoperating (Income) Expense 42 Income Taxes 100 Operating Profit (Loss) (GAAP) $ 531 $ (239) $ 554 $ (86) $ 760 Other Operating Profit Adjustments1 — 432 — — 432 Amortization of Intangible Assets 228 150 48 — 426 Adjusted Operating Profit (Non-GAAP)2 759 343 602 (86) 1,618 Depreciation 38 45 100 2 185 Adjusted EBITDA (Non-GAAP) $ 797 $ 388 $ 702 $ (84) $ 1,803 Interest, Net (63) Other Nonoperating Income (Expense) (42) Income Taxes (100) Other Operating Profit Adjustments1 (432) Amortization of Intangible Assets (426) Depreciation (185) Net Earnings (GAAP) $ 555 Sales (GAAP) $ 1,850 $ 1,777 $ 2,309 $ 5,936 Net Earnings Margin (GAAP) 9.3 % Operating Profit (Loss) Margin (GAAP) 28.7 % (13.4) % 24.0 % 12.8 % Adjusted Operating Profit Margin (Non-GAAP)3 41.0 % 19.3 % 26.1 % 27.3 % Adjusted EBITDA Margin (Non-GAAP)4 43.1 % 21.8 % 30.4 % 30.4 % 1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments. 2 Adjusted Operating Profit (Non-GAAP) is defined as Operating Profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined). 3 Adjusted Operating Profit Margin (Non-GAAP) is defined as Adjusted Operating Profit (Non-GAAP) divided by Sales (GAAP). 4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP). DANAHER CORPORATION Non-GAAP Profitability Measures ($ in millions) 4 -- 15 of 28 -- Three-Month Period Ended June 28, 2024 Biotechnology Life Sciences Diagnostics Other Total Company Net Earnings (GAAP) $ 907 Interest, Net 26 Other Nonoperating (Income) Expense 59 Income Taxes 176 Operating Profit (GAAP) $ 462 $ 233 $ 556 $ (83) $ 1,168 Other Operating Profit Adjustments1 — — — — — Amortization of Intangible Assets 214 140 48 — 402 Adjusted Operating Profit (Non-GAAP)2 676 373 604 (83) 1,570 Depreciation 35 41 100 2 178 Adjusted EBITDA (Non-GAAP) $ 711 $ 414 $ 704 $ (81) $ 1,748 Interest, Net (26) Other Nonoperating Income (Expense) (59) Income Taxes (176) Other Operating Profit Adjustments1 — Amortization of Intangible Assets (402) Depreciation (178) Net Earnings (GAAP) $ 907 Sales (GAAP) $ 1,713 $ 1,770 $ 2,260 $ 5,743 Net Earnings Margin (GAAP) 15.8 % Operating Profit Margin (GAAP) 27.0 % 13.2 % 24.6 % 20.3 % Adjusted Operating Profit Margin (Non-GAAP)3 39.5 % 21.1 % 26.7 % 27.3 % Adjusted EBITDA Margin (Non-GAAP)4 41.5 % 23.4 % 31.2 % 30.4 % 1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments. 2 Adjusted Operating Profit (Non-GAAP) is defined as Operating Profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined). 3 Adjusted Operating Profit Margin (Non-GAAP) is defined as Adjusted Operating Profit (Non-GAAP) divided by Sales (GAAP). 4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP). DANAHER CORPORATION Non-GAAP Profitability Measures ($ in millions) 5 -- 16 of 28 -- Six-Month Period Ended June 27, 2025 Biotechnology Life Sciences Diagnostics Other Total Company Net Earnings (GAAP) $ 1,509 Interest, Net 129 Other Nonoperating (Income) Expense 121 Income Taxes 275 Operating Profit (Loss) (GAAP) $ 972 $ (38) $ 1,272 $ (172) $ 2,034 Other Operating Profit Adjustments1 15 432 — — 447 Amortization of Intangible Assets 441 299 96 — 836 Adjusted Operating Profit (Non-GAAP)2 1,428 693 1,368 (172) 3,317 Depreciation 72 90 200 4 366 Adjusted EBITDA (Non-GAAP) $ 1,500 $ 783 $ 1,568 $ (168) $ 3,683 Interest, Net (129) Other Nonoperating Income (Expense) (121) Income Taxes (275) Other Operating Profit Adjustments1 (447) Amortization of Intangible Assets (836) Depreciation (366) Net Earnings (GAAP) $ 1,509 Sales (GAAP) $ 3,462 $ 3,457 $ 4,758 $ 11,677 Net Earnings Margin (GAAP) 12.9 % Operating Profit (Loss) Margin (GAAP) 28.1 % (1.1) % 26.7 % 17.4 % Adjusted Operating Profit Margin (Non-GAAP)3 41.2 % 20.0 % 28.8 % 28.4 % Adjusted EBITDA Margin (Non-GAAP)4 43.3 % 22.6 % 33.0 % 31.5 % 1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments. 2 Adjusted Operating Profit (Non-GAAP) is defined as Operating Profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined). 3 Adjusted Operating Profit Margin (Non-GAAP) is defined as Adjusted Operating Profit (Non-GAAP) divided by Sales (GAAP). 4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP). DANAHER CORPORATION Non-GAAP Profitability Measures ($ in millions) 6 -- 17 of 28 -- Six-Month Period Ended June 28, 2024 Biotechnology Life Sciences Diagnostics Other Total Company Net Earnings (GAAP) $ 1,995 Interest, Net 31 Other Nonoperating (Income) Expense 95 Income Taxes 359 Operating Profit (GAAP) $ 787 $ 468 $ 1,386 $ (161) $ 2,480 Other Operating Profit Adjustments1 — 25 — — 25 Amortization of Intangible Assets 432 281 96 — 809 Adjusted Operating Profit (Non-GAAP)2 1,219 774 1,482 (161) 3,314 Depreciation 77 79 197 4 357 Adjusted EBITDA (Non-GAAP) $ 1,296 $ 853 $ 1,679 $ (157) $ 3,671 Interest, Net (31) Other Nonoperating Income (Expense) (95) Income Taxes (359) Other Operating Profit Adjustments1 (25) Amortization of Intangible Assets (809) Depreciation (357) Net Earnings (GAAP) $ 1,995 Sales (GAAP) $ 3,237 $ 3,515 $ 4,787 $ 11,539 Net Earnings Margin (GAAP) 17.3 % Operating Profit Margin (GAAP) 24.3 % 13.3 % 29.0 % 21.5 % Adjusted Operating Profit Margin (Non-GAAP)3 37.7 % 22.0 % 31.0 % 28.7 % Adjusted EBITDA Margin (Non-GAAP)4 40.0 % 24.3 % 35.1 % 31.8 % 1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments. 2 Adjusted Operating Profit (Non-GAAP) is defined as Operating Profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined). 3 Adjusted Operating Profit Margin (Non-GAAP) is defined as Adjusted Operating Profit (Non-GAAP) divided by Sales (GAAP). 4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by Sales (GAAP). DANAHER CORPORATION Non-GAAP Profitability Measures ($ in millions) 7 -- 18 of 28 -- Three-Month Period Ended June 27, 2025 Cost of sales Gross profit margin Operating profit Operating profit margin Earnings before income taxes Income taxes Net earnings for calculation of diluted earnings per common share Diluted net earnings per common share Reported (GAAP) $ (2,413) 59.3 % $ 760 12.8 % $ 655 $ (100) $ 555 $ 0.77 Amortization of acquisition-related intangible assetsA — — 426 7.2 426 426 0.59 Fair value net (gains) losses on investmentsB — — — — 44 44 0.06 ImpairmentsC — — 432 7.3 432 432 0.60 Tax effect of the above adjustmentsF (187) (187) (0.26) Discrete tax adjustmentsG 22 22 0.03 Rounding — — — — — — — 0.01 Adjusted (Non-GAAP) $ (2,413) 59.3 % $ 1,618 27.3 % $ 1,557 $ (265) $ 1,292 $ 1.80 Three-Month Period Ended June 27, 2025 Selling, general and administrative expenses Selling, general and administrative expenses as a % of sales Research and development expenses Research and development expenses as a % of sales Nonoperating income (expense), net (excluding interest) Interest income (expense), net Reported (GAAP) $ (2,360) (39.8) % $ (403) (6.8) % $ (42) $ (63) Amortization of acquisition-related intangible assetsA 426 7.2 — — — — Fair value net (gains) losses on investmentsB — — — — 44 — ImpairmentsC 432 7.3 — — — — Adjusted (Non-GAAP) $ (1,502) (25.3) % $ (403) (6.8) % $ 2 $ (63) DANAHER CORPORATION Other Non-GAAP Adjusted P&L Measures ($ in millions, except per share data) 8 -- 19 of 28 -- Three-Month Period Ended June 28, 2024 Cost of sales Gross profit margin Operating profit Operating profit margin Earnings before income taxes Income taxes Net earnings for calculation of diluted earnings per common share Diluted net earnings per common share Reported (GAAP) $ (2,315) 59.7 % $ 1,168 20.3 % $ 1,083 $ (176) $ 907 $ 1.22 Amortization of acquisition-related intangible assetsA — — 402 7.0 402 402 0.54 Fair value net (gains) losses on investmentsB — — — — 59 59 0.08 Tax effect of the above adjustmentsF (85) (85) (0.11) Discrete tax adjustmentsG (9) (9) (0.01) Adjusted (Non-GAAP) $ (2,315) 59.7 % $ 1,570 27.3 % $ 1,544 $ (270) $ 1,274 $ 1.72 Three-Month Period Ended June 28, 2024 Selling, general and administrative expenses Selling, general and administrative expenses as a % of sales Research and development expenses Research and development expenses as a % of sales Nonoperating income (expense), net (excluding interest) Interest income (expense), net Reported (GAAP) $ (1,869) (32.5) % $ (391) (6.8) % $ (59) $ (26) Amortization of acquisition-related intangible assetsA 402 7.0 — — — — Fair value net (gains) losses on investmentsB — — — — 59 — Adjusted (Non-GAAP) $ (1,467) (25.5) % $ (391) (6.8) % $ — $ (26) DANAHER CORPORATION Other Non-GAAP Adjusted P&L Measures ($ in millions, except per share data) 9 -- 20 of 28 -- Six-Month Period Ended June 27, 2025 Cost of sales Gross profit margin Operating profit Operating profit margin Earnings before income taxes Income taxes Net earnings for calculation of diluted earnings per common share Diluted net earnings per common share 5 Reported (GAAP) $ (4,643) 60.2 % $ 2,034 17.4 % $ 1,784 $ (275) $ 1,509 $ 2.10 Amortization of acquisition-related intangible assetsA — — 836 7.2 836 836 1.16 Fair value net (gains) losses on investmentsB — — — — 134 134 0.19 ImpairmentsC 15 0.1 447 3.8 447 447 0.62 Gain on a product line dispositionD — — — — (9) (9) (0.01) Tax effect of the above adjustmentsF (281) (281) (0.39) Discrete tax adjustmentsG 12 12 0.02 Rounding — 0.1 — — — — — (0.01) Adjusted (Non-GAAP) $ (4,628) 60.4 % $ 3,317 28.4 % $ 3,192 $ (544) $ 2,648 $ 3.68 Six-Month Period Ended June 27, 2025 Selling, general and administrative expenses Selling, general and administrative expenses as a % of sales Research and development expenses Research and development expenses as a % of sales Nonoperating income (expense), net (excluding interest) Interest income (expense), net Reported (GAAP) $ (4,218) (36.1) % $ (782) (6.7) % $ (121) $ (129) Amortization of acquisition-related intangible assetsA 836 7.2 — — — — Fair value net (gains) losses on investmentsB — — — — 134 — ImpairmentsC 432 3.7 — — — — Gain on a product line dispositionD — — — — (9) — Rounding — (0.1) — — — — Adjusted (Non-GAAP) $ (2,950) (25.3) % $ (782) (6.7) % $ 4 $ (129) 5 Net earnings per diluted common share for the relevant three-month periods may not add to the year-to-date amounts due to rounding. DANAHER CORPORATION Other Non-GAAP Adjusted P&L Measures ($ in millions, except per share data) 10 -- 21 of 28 -- Six-Month Period Ended June 28, 2024 Cost of sales Gross profit margin Operating profit Operating profit margin Earnings before income taxes Income taxes Net earnings for calculation of diluted earnings per common share Diluted net earnings per common share 5 Reported (GAAP) $ (4,624) 59.9 % $ 2,480 21.5 % $ 2,354 $ (359) $ 1,995 $ 2.68 Amortization of acquisition-related intangible assetsA — — 809 7.0 809 809 1.09 Fair value net (gains) losses on investmentsB — — — — 96 96 0.13 Acquisition-related itemsE 25 0.2 25 0.2 25 25 0.03 Tax effect of the above adjustmentsF (171) (171) (0.23) Discrete tax adjustmentsG (45) (45) (0.06) Rounding — — — — — — — (0.01) Adjusted (Non-GAAP) $ (4,599) 60.1 % $ 3,314 28.7 % $ 3,284 $ (575) $ 2,709 $ 3.63 Six-Month Period Ended June 28, 2024 Selling, general and administrative expenses Selling, general and administrative expenses as a % of sales Research and development expenses Research and development expenses as a % of sales Nonoperating income (expense), net (excluding interest) Interest income (expense), net Reported (GAAP) $ (3,676) (31.9) % $ (759) (6.6) % $ (95) $ (31) Amortization of acquisition-related intangible assetsA 809 7.0 — — — — Fair value net (gains) losses on investmentsB — — — — 96 — Rounding — 0.1 — — — — Adjusted (Non-GAAP) $ (2,867) (24.8) % $ (759) (6.6) % $ 1 $ (31) 5 Net earnings per diluted common share for the relevant three-month periods may not add to the year-to-date amounts due to rounding. DANAHER CORPORATION Other Non-GAAP Adjusted P&L Measures ($ in millions, except per share data) 11 -- 22 of 28 -- A Amortization of acquisition-related intangible assets in the following historical periods (only the pretax amounts set forth below are reflected in the amortization line item above): Three-Month Period Ended Six-Month Period Ended June 27, 2025 June 28, 2024 June 27, 2025 June 28, 2024 Pretax $ 426 $ 402 $ 836 $ 809 After-tax 354 331 694 667 B Net (gains) losses on the Company's equity and limited partnership investments recorded in the following historical periods (only the pretax amounts set forth below are reflected in the fair value net (gains) losses on investments line above): Three-Month Period Ended Six-Month Period Ended June 27, 2025 June 28, 2024 June 27, 2025 June 28, 2024 Pretax $ 44 $ 59 $ 134 $ 96 After-tax 33 45 101 73 C Impairment charges related to a trade name in the Life Sciences segment recorded in both the three and six-month periods ended June 27, 2025 ($432 million pretax as reported in this line item, $328 million after-tax) and a facility in the Biotechnology segment recorded in the six-month period ended June 27, 2025 ($15 million pretax as reported in this line item, $11 million after-tax). D Gain on a product line disposition in the six-month period ended June 27, 2025 ($9 million pretax as reported in this line item, $7 million after-tax). E Costs incurred for the fair value adjustment to inventory related to the acquisition of Abcam plc (“Abcam”) for the six-month period ended June 28, 2024 ($25 million pretax as reported in this line item, $19 million after-tax). F This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher’s overall estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment. G Discrete tax adjustments and other tax-related adjustments for the three-month period ended June 27, 2025, include the impact of net discrete tax charges of $22 million related primarily to changes in uncertain tax positions and other items. Discrete tax adjustments and other tax-related adjustments for the six-month period ended June 27, 2025, include the impact of net discrete tax charges of $12 million related primarily to the release of reserves for uncertain tax positions due to the expiration of statutes of limitations, partially offset by changes in uncertain tax positions and other items. Discrete tax adjustments and other tax-related adjustments for the three-month period ended June 28, 2024, include the impact of net discrete tax benefits of $9 million due principally to excess tax benefits from stock-based compensation. Discrete tax adjustments and other tax-related adjustments for the six-month period ended June 28, 2024, include net discrete tax benefits of $45 million related primarily to excess tax benefits from stock-based compensation, release of reserves for uncertain tax positions due to the expiration of statutes of limitation and changes in estimates associated with prior period uncertain tax positions. DANAHER CORPORATION Other Non-GAAP Adjusted P&L Measures ($ in millions, except per share data) 12 -- 23 of 28 -- Segments Total Company Biotechnology Life Sciences Diagnostics Three-Month Period Ended June 28, 2024 Operating Profit Margins (GAAP) 20.30 % 27.00 % 13.20 % 24.60 % Second quarter 2025 impact from operating profit margin of businesses that have been owned for less than one year or were disposed of during such period and did not qualify as discontinued operations (0.30) — (0.75) (0.15) Second quarter 2025 impairment charge related to a trade name in the Life Sciences segment (7.30) — (24.30) — Year-over-year core operating profit margin changes for the second quarter 2025 (defined as all year-over-year operating profit margin changes other than the changes identified in the line items above) (non-GAAP) 0.10 1.70 (1.55) (0.45) Three-Month Period Ended June 27, 2025 Operating Profit Margins (GAAP) 12.80 % 28.70 % (13.40) % 24.00 % Segments Total Company Biotechnology Life Sciences Diagnostics Six-Month Period Ended June 28, 2024 Operating Profit Margins (GAAP) 21.50 % 24.30 % 13.30 % 29.00 % First half of 2025 impact from operating profit margins of businesses that have been owned for less than one year or were disposed of during such period and did not qualify as discontinued operations (0.30) — (0.60) (0.15) First half of 2025 impairment charge related to a trade name in the Life Sciences segment and a facility in the Biotechnology segment (3.85) (0.45) (12.50) — First half of 2024 acquisition-related fair value adjustment to inventory related to the acquisition of Abcam 0.20 — 0.70 — Year-over-year core operating profit margin changes for the first half of 2025 (defined as all year-over-year operating profit margin changes other than the changes identified in the line items above) (non-GAAP) (0.15) 4.25 (2.00) (2.15) Six-Month Period Ended June 27, 2025 Operating Profit Margins (GAAP) 17.40 % 28.10 % (1.10) % 26.70 % DANAHER CORPORATION Operating Profit Margins and Year-Over-Year Core Operating Profit Margin Changes 13 -- 24 of 28 -- Three-Month Period Ended Year-over-Year Change Six-Month Period Ended Year-over-Year Change June 27, 2025 June 28, 2024 June 27, 2025 June 28, 2024 Total Cash Flow: Net cash provided by operating activities (GAAP) $ 1,338 $ 1,417 $ 2,637 $ 3,156 Total cash used in investing activities (GAAP) $ (258) $ (360) $ (500) $ (681) Total cash used in financing activities (GAAP) $ (247) $ (5,715) $ (1,502) $ (5,848) Free Cash Flow: Net cash provided by operating activities (GAAP) $ 1,338 $ 1,417 ~ (5.5) % $ 2,637 $ 3,156 ~ (16.5) % Less: payments for additions to property, plant & equipment (capital expenditures) (GAAP) (248) (287) (493) (578) Plus: proceeds from sales of property, plant & equipment (capital disposals) (GAAP) 4 1 10 1 Free cash flow (non-GAAP) $ 1,094 $ 1,131 ~ (3.5) % $ 2,154 $ 2,579 ~ (16.5) % Operating Cash Flow to Net Earnings Conversion Ratio: Net cash provided by operating activities (GAAP) $ 1,338 $ 1,417 $ 2,637 $ 3,156 Net earnings (GAAP) 555 907 1,509 1,995 Operating cash flow to net earnings conversion ratio (GAAP) 2.41 1.56 1.75 1.58 Free Cash Flow to Net Earnings Conversion Ratio: Free cash flow from above (non-GAAP) $ 1,094 $ 1,131 $ 2,154 $ 2,579 Net earnings (GAAP) 555 907 1,509 1,995 Free cash flow to net earnings conversion ratio (non- GAAP) 1.97 1.25 1.43 1.29 We define free cash flow as operating cash flows, less payments for additions to property, plant and equipment (“capital expenditures”) plus the proceeds from sales of plant, property and equipment (“capital disposals”). DANAHER CORPORATION Total Cash Flow, Free Cash Flow, Operating Cash Flow to Net Earnings Conversion Ratio and Free Cash Flow to Net Earnings Conversion Ratio ($ in millions) 14 -- 25 of 28 -- Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Danaher Corporation’s (“Danaher” or the “Company”) results that, when reconciled to the corresponding GAAP measure, help our investors: • with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to prior and future periods and to our peers; • with respect to core sales, identify underlying growth trends in our business and compare our sales performance with prior and future periods and to our peers; and • with respect to free cash flow and related non-GAAP cash flow measures (the “FCF Measure”), understand Danaher’s ability to generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of free cash flow is that it does not take into account the Company’s debt service requirements and other non-discretionary expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures). Management uses the non-GAAP measures referenced above to measure the Company’s operating and financial performance, and uses core sales and non- GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share and the FCF Measure in the Company’s executive compensation program. • The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons: ◦ Amortization of Intangible Assets: We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition’s purchase price allocated to intangible assets and related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies. We believe however that it is important for investors to understand that such intangible assets contribute to sales generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized. ◦ Restructuring Charges: We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the ordinary course of our business and we believe are not indicative of Danaher’s ongoing operating costs in a given period, we exclude these costs to facilitate a more consistent comparison of operating results over time. ◦ Other Adjustments: With respect to the other items excluded from Adjusted Diluted Net Earnings Per Common Share, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult. • With respect to core operating profit margin changes, in addition to the explanation set forth in the bullets above relating to "restructuring charges” and “other adjustments”, we exclude the impact of businesses owned for less than one year (or disposed of during such period and not treated as discontinued operations) because the timing, size, number and nature of such transactions can vary significantly from period to period and may obscure underlying business trends and make comparisons of long-term performance difficult. • We calculate adjusted EBITDA by adding to operating profit amounts equal to depreciation and amortization and making the other adjustments reflected in the applicable tables above, which allows us to calculate and disclose such measure by segment. Given Danaher’s diversification, we believe this helps our investors compare the profitability of our individual segments to peer companies with like business lines. DANAHER CORPORATION Statement Regarding Non-GAAP Measures 15 -- 26 of 28 -- • With respect to core sales, (1) we exclude the impact of currency translation because it is not under management’s control, is subject to volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult. • With respect to the FCF Measure, we deduct payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company’s capital expenditure requirements. DANAHER CORPORATION Statement Regarding Non-GAAP Measures 16 -- 27 of 28 -- 17 -- 28 of 28 --